Doug Drysdale

I'm Doug, founder of Katogen and a biopharma operator with nearly two decades running companies through growth, turnarounds, and major deals. As Founding CEO of Alvogen, I scaled the business to $500M in revenue across 35 countries. At Cybin, I took a psychedelic-medicine company from molecule inception to Phase 3 trials and FDA Breakthrough Therapy designation in three years. Across four CEO roles, I've led 17 acquisitions and raised over $4.5 billion in capital. Ask me about building and scaling biopharma companies, M&A and capital strategy, psychedelic and neurological therapeutics, and mental health innovation.